These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33339135)

  • 1. The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond
    Marsavela G; Johansson PA; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Khattak MA; Meniawy TM; Amanuel B; Millward M; Hayward NK; Ziman MR; Gray ES; Calapre L
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
    Marsavela G; Lee J; Calapre L; Wong SQ; Pereira MR; McEvoy AC; Reid AL; Robinson C; Warburton L; Abed A; Khattak MA; Meniawy TM; Dawson SJ; Sandhu S; Carlino MS; Menzies AM; Scolyer RA; Long GV; Amanuel B; Millward M; Ziman MR; Rizos H; Gray ES
    Clin Cancer Res; 2020 Nov; 26(22):5926-5933. PubMed ID: 33067256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
    Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
    Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
    Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
    Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study.
    Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Varey E; Khammari A; Dréno B; Denis MG
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
    Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
    Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
    Ashida A; Sakaizawa K; Uhara H; Okuyama R
    Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.
    Forschner A; Weißgraeber S; Hadaschik D; Schulze M; Kopp M; Kelkenberg S; Sinnberg T; Garbe C; Biskup S; Battke F
    Onco Targets Ther; 2020; 13():5017-5032. PubMed ID: 32581559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
    Váraljai R; Wistuba-Hamprecht K; Seremet T; Diaz JMS; Nsengimana J; Sucker A; Griewank K; Placke JM; Horn PA; von Neuhoff N; Shannan B; Chauvistré H; Vogel FCE; Horn S; Becker JC; Newton-Bishop J; Stang A; Neyns B; Weide B; Schadendorf D; Roesch A
    JCO Precis Oncol; 2020; 3():. PubMed ID: 32914028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of BRAF
    Tang H; Kong Y; Si L; Cui C; Sheng X; Chi Z; Dai J; Yu S; Ma M; Wu X; Yu J; Xu T; Yu H; Yan J; Guo J
    Oncol Lett; 2018 Feb; 15(2):1839-1844. PubMed ID: 29434880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
    Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
    Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic
    Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Frénard C; Varey E; Hofman P; Khammari A; Dréno B; Denis MG
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
    Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
    Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
    Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
    J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
    Calapre L; Warburton L; Millward M; Gray ES
    BMC Cancer; 2019 Nov; 19(1):1109. PubMed ID: 31727009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.
    Fitzgerald S; Blenkiron C; Stephens R; Mathy JA; Somers-Edgar T; Rolfe G; Martin R; Jackson C; Eccles M; Robb T; Rodger E; Lawrence B; Guilford P; Lasham A; Print CG
    Mol Diagn Ther; 2023 Jul; 27(4):537-550. PubMed ID: 37099071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients.
    Di Nardo L; Del Regno L; Di Stefani A; Mannino M; Fossati B; Catapano S; Quattrini L; Pellegrini C; Cortellini A; Parisi A; Capoluongo E; Autilio C; Fargnoli MC; Peris K
    Exp Dermatol; 2023 Oct; 32(10):1785-1793. PubMed ID: 37533342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
    Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
    Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.